Come up with a name for your new list and we'll add to it:
Edimer Pharmaceuticals raised a round of funding on November 01, 2010. Investors include
Qualifying Therapeutic Discovery Project.
Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). XLHED is a rare orphan disease that causes a range of symptoms including…